Shots: Bio-Thera to receive an up front, milestones along with royalties on product sales & will be responsible for the development, manufacturing, supply of BAT1706 Sandoz to get rights for […]readmore
Tags : Avastin
Shots: The BLA submission is based on data from P-III clinical comparison study that demonstrated BAT1706 is highly similar to reference bevacizumab in clinical efficacy, safety, and immunogenicity. The anticipated […]readmore
Shots: The approval is based on P-III IMbrave150 study involves assessing of Tecentriq (1200mg) + Avastin (15 mg/kg) on day 1 of each 21-day cycle vs sorafenib (400mg, bid) on […]readmore
Shots: The company has submitted an MAAA for BAT1706 to EMA. Bio-Thera seeks a commercial license for all approved indications of bevacizumab in the EU Member States, Iceland, Norway, and […]readmore
Shots: The approval was based on the P-III IMbrave150 study (n=501) assessing the combination of Tecentriq (1200 mg, IV) and Avastin (15 mg/kg, IV) or sorafenib (400 mg, bid) in […]readmore
Shots: The approval is based on P-lll IMbrave150 study assessing Tecentriq (1200mg) and Avastin (100 mg/4 mL and 400 mg/16 mL) vs sorafenib in 501 patients in a ratio (2:1) […]readmore
The average life expectancy span of Human Beings are increased due to better medical facilities and drugs developed by Biopharma companies. Pharmaceutical products or drugs or medicines are being produced […]readmore
Shots: The approval is based on P-III IMbrave150 study assessing Tecentriq (IV, 1200mg on day 1 of each 21-day cycle) and Avastin (IV, 15 mg/kg on day 1 of each […]readmore
Shots: The US FDA has accepted the BLA for Mylan’s MYL-1402O, a proposed biosimilar to Avastin (bevacizumab) for review under the 351(k)pathway with its anticipated BsUFA date as Dec 27, […]readmore
Shots: The P-III IMbrave150 study involves assessing Tecentriq (IV, 1200mg) + Avastin (IV, 15mg/kg) vs Sorafenib (400mg, bid) in 501 (194 from China) patients in a ratio (2:1) in patients […]readmore